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Intravenous self-administration studies 
with /-deprenyl (selegiline) in monkeys* 
/-Deprenyl and its stereoisomer d-deprenyl did not maintain intravenous self-administration behavior in 
rhesus monkeys. In contrast, /-methamphetamine, the major metabolite of /-deprenyl, as well as the 
baseline drug, cocaine, maintained high rates of intravenous self-administration behavior. Treatment 
with /-deprenyl doses up to 1.0 mg/kg before self-administration sessions failed to alter self-administra- 
tion of either cocaine or /-methamphetamine. Thus /-deprenyl did not appear to have cocaine- or meth- 
amphetamine-like reinforcing properties in monkeys and was ineffective in altering established patterns 
of psychomotor-stimulant self-administration behavior. These results support clinical findings that de- 
spite long-term use of /-deprenyl for the treatment of Parkinson's disease by large numbers of patients, 
no instances of abuse have been documented. /-Deprenyl has recently been suggested as a potential med- 
ication for the treatment of various types of drug abuse, including cocaine abuse, but its failure to pro- 
duce selective effects in decreasing cocaine or methamphetamine self-administration behavior in the 
present experiments makes such an application seem unlikely. (CLIN PHARMACOL THER 1994;56:774-80.) 
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*The drug names d- and /-methamphetamine used in this article have 
been commonly employed in the experimental literature and are 
used herein. It should be noted, however, that methamphetamine 
does not exist in racemic form but d-methamphetamine instead re- 
fers to the d-isomer of N-methylamphetamine and that 1-metham- 
phetamine is more correctly named /-N-methylamphetamine. 
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/-Deprenyl (selegiline) has been known for several 
years to increase and prolong the effectiveness of 
/-dihydroxyphenylalanine (L-dopa) in the treatment of 
the symptoms of Parkinson's disease." More re- 
cently, /-deprenyl alone has been found to slow the 
progression of Parkinson's disease and to delay the 
need for L-dopa therapy.5'6 However, the mechanism 
by which it produces these therapeutic benefits is not 
clearly understood.7 
/-Deprenyl is a selective and irreversible antago- 
nist of monoamine oxidase B (MAO-B),8'9 an enzyme 
that primarily has an extraneuronal location in the 
human brain10" and that deaminates synaptic accu- 
mulations of cathecolamines and 13-phenylethylamine 
(13_pEA).12,13 /-Deprenyl inhibits deamination of do- 
pamine in vitro, and its mechanism of therapeutic ac- 
tion was thought to be by increasing brain levels of 
dopamine in vivo. However, MAO-B is not present 
within dopaminergic nerve terminals in human brain 
and does not appear to be a primary contributor to do- 
pamine's inactivation in vivo in humans. However, 
the administration of /-deprenyl to intact rats, which 
show a greater distribution of MAO-B in brain than in 
humans, can produce increased dopamine levels.14 
Recent studies in rats have suggested that /-depre- 
nyl's mechanism of therapeutic effect might be from 
its metabolic conversion to /-methamphetamine15.16 or 
that its inhibition of MAO-B might lead to increases 
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in striatal levels of 13-PEA, which in turn might poten- 
tiate the responses of striatal neurons to dopamine.17 
Both of these mechanisms of action of /-deprenyl sug- 
gest the possibility that this drug might be abused by 
susceptible individuals. d-Methamphetamine has ac- 
knowledged abuse potential in humans, and 1-metham- 
phetamine is an effective reinforcer of intravenous 
self-administration behavior in the rat.18 Phenylethy- 
lamine is a naturally occurring amine that is structur- 
ally similar to amphetamine. The administration of 
large doses of 13-PEA to rhesus monkeys can produce 
an amphetamine-like stereotypy.19 This compound has 
been shown to maintain intravenous self-administra- 
tion behavior in dogs.20'21 Thus medications that in- 
crease levels of 13-PEA may have potential for abuse 
by humans. 
Indications that /-deprenyl itself might have abuse 
liability come primarily from preclinical studies in 
which it has been found to have effects in common 
with amphetamine or cocaine. Several investigators 
have reported that /-deprenyl has cocaine-like discrim- 
inative stimulus properties in rats22,23 and pigeons.24 
The racemic form of deprenyl but not other MAO-B 
inhibitors have discriminative stimulus effects in com- 
mon with d-amphetamine.25 Yasar et al.26 and Yasar 
and Bergman27 found that in animals trained to dis- 
criminate the stimulus effects of d-amphetamine or 
d-methamphetamine from saline solution, large doses 
of /-deprenyl had discriminative stimulus effects in 
common with the d - and /-isomers of amphetamine in 
rats and the d - and /-isomers of methamphetamine in 
squirrel monkeys. 
The abuse liability of /-deprenyl can be assessed more 
directly by evaluation of its ability to maintain drug- 
seeking and drug-taking behavior, that is, its effective- 
ness as a reinforcer of self-administration behavior.28 
Studies in which intravenous drug injection is contin- 
gent on behavioral responses made by experithental an- 
imals have shown that many of the drugs that are sub- 
ject to abuse by humans are self-administered by 
experimental animals 29 In the current study the rein- 
forcing effects of both the 1- and the d-stereoisomers of 
deprenyl were evaluated in rhesus monkeys that were 
experienced with self-administration of cocaine. In ad- 
dition, the reinforcing effects of /-methamphetamine, 
the major metabolite of /-deprenyl, were evaluated in 
these monkeys, and the ability of /-deprenyl to modify 
responding maintained by either cocaine or /-metham- 
phetamine was determined Finally, the effects of 1- 
deprenyl on food-maintained behavior were evaluated 
in an additional group of monkeys. 
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METHODS 
The reinforcing effects of /-deprenyl, d-deprenyl, 
and /-methamphetamine were evaluated with operant 
procedures in rhesus monkeys (Macaca mulaua) by 
making specified doses of each drug available for in- 
travenous self-administration. Results with /-deprenyl 
have been reported previously.' Using apparatus first 
described by Deneau et al.29 and modified as de- 
scribed by Winger et al.,3° each monkey was surgi- 
cally prepared with a long-term venous catheter and 
individually housed 24 hours a day in a stainless-steel 
cage containing a side panel with two response levers 
and three stimulus lights. Each monkey wore a har- 
ness that was connected to a flexible steel spring arm, 
which was designed to allow the animal free move- 
ment within the cage but to protect the venous cathe- 
ter. The catheter was led through the arm to an injec- 
tion pump (model MHRK 55 Watson and Marlow 
Co.) that was located behind the cage. 
A procedure for rapidly evaluating the reinforcing 
effects of intravenously delivered drugs in rhesus 
monkeys was used.3° Silicone rubber catheters (Max- 
Med. Inc., Portage, Wis.) were surgically implanted 
in a jugular, femoral, or brachial vein with ketamine 
(10 mg/kg) and xylamine (2 mg/kg) anesthetic. Dur- 
ing twice-daily experimental sessions, one of the stim- 
ulus lights was illuminated red, which signaled drug 
availability. In the presence of the red light, 30 re- 
sponses (fixed ratio 30) on the lever beneath the light 
resulted in the intravenous delivery of drug or saline 
solution. A center, green, stimulus light was on dur- 
ing pump activation. Each injection was followed by a 
45-second blackout period, when all lights were extin- 
guished and lever presses had no programmed conse- 
quences. Experimental sessions were limited to 130 
minutes, and two sessions were scheduled each day, 
separated by at least 4 hours. Each session was di- 
vided into four components; each component was sig- 
naled by illumination of the red stimulus light and was 
separated from the following component by a 10- 
minute intercomponent interval. During the intercom- 
ponent interval, no lights were illuminated, and re- 
sponses on the lever had no programmed conse- 
quences. 
With this rapid-evaluation procedure, a unique dose 
per injection of drug was available during each of the 
four components of a session. A component ended af- 
ter 20 injections of that particular dose were earned or 
25 minutes had elapsed, whichever occurred first. 
Drug concentration was kept constant throughout a 
session and doses were altered by adjusting the dura- 
776 Winger et al. 
tion of activation of the injection pump. Doses were 
evaluated in one-half logarithm unit steps. Monkeys 
were initially trained with /-cocaine in doses of 0.0003 
(0.5 second), 0.001 (1.7 seconds), 0.003 (5 seconds), 
and 0.01 (16.7 seconds) mg/kg per injection. Four 
dose orders were used: ascending, descending, and 
two mixed orders. Selection of dose order was made 
randomly. 
When saline solution was substituted, injection du- 
rations continued to be different in each component, 
as they were with drug injections. If rates of saline- 
maintained responding were higher than 0 5 response 
per second at any injection duration, saline solution 
was substituted again until rates were consistently be- 
low 0.5 response per second. Different doses of /-de- 
prenyl, d-deprenyl, /-methamphetamine, or /-cocaine 
were substituted during single sessions after rates of 
saline-maintained responding were low. Full dose-re- 
sponse curves were obtained by testing overlapping 
ranges of cumulative doses during different test ses- 
sions. When higher or lower dose ranges were tested, 
drug concentration was altered: injection durations 
were always 0.5, 1.7, 5 or 16.7 seconds. Before some 
sessions, an intravenous dose of /-deprenyl was given 
through the catheter 30 minutes before the start of the 
session (pretreatment), with different doses of /-co- 
caine, /-methamphetamine, or saline available for self- 
administration during the session. 
Nine rhesus monkeys (six males and three females) 
served as subjects in the self-administration studies. 
Three monkeys were used to evaluate the reinforcing 
effects of d-deprenyl. Five monkeys (including the 
three used to evaluate the reinforcing effects of d- 
deprenyl) were used as subjects for evaluation of the 
effects of /-deprenyl on the reinforcing effects of co- 
caine. Three monkeys (two of which participated in 
one or more of the other studies) were used for evalu- 
ation of the effects of /-deprenyl on the reinforcing ef- 
fects of /-methamphetamine. 
The reinforcing effects of d - and /-deprenyl were 
evaluated between one and six times in each monkey; 
a different dose range was typically used when more 
than one evaluation was made. The effects of pretreat- 
ment with /-deprenyl (1.0 and 3.2 mg/kg, intrave- 
nously) were usually evaluated only once in monkeys 
self-administering cocaine; /-deprenyl (1.0 mg/kg, in- 
travenously) was administered between two and four 
times to monkeys self-administering /-methamphet- 
amine. 
An additional three male rhesus monkeys served as 
subjects to evaluate the effects of /-deprenyl on food- 
reinforced behavior. These animals were on a sched- 
ule of limited feeding, receiving 20 to 25 Purina high- 
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protein monkey chows each day. The apparatus used 
in this portion of the experiment has been described 
by Negus et al.31 Subjects remained in their home 
cages during testing. An experimental panel contain- 
ing two levers (model PRL-001, BRS/LVE, Laurel, 
Md.), on either side of a food receptacle, with colored 
stimulus lights above each of the levers, was mounted 
on one wall of each cage. The reinforcer was a 300 
mg, banana-flavored pellet (formula Gil, P.J. Noyes 
Co., Lancaster, N.H.), delivered by an externally 
mounted pellet dispenser (model G5210, Gerbrands 
Co., Arlington, Mass.). 
Sessions were carried out five to six days per week. 
A session was initiated with a timeout period during 
which no stimulus lights were illuminated and re- 
sponses on the levers had no programmed conse- 
quences. After 10 minutes, the stimulus lights were 
turned on; in the presence of the lights 30 responses 
on either lever (fixed ratio 30) resulted in the delivery 
of a food pellet. The lights were extinguished again 
for 10 minutes after 10 pellets had been delivered or 5 
minutes had passed, whichever occurred first, which 
initiated another 15-minute cycle (10-minute timeout 
followed by a 5-minute response period). A daily ses- 
sion consisted of five of these cycles; sterile water or a 
sham injection was given at the beginning of each 
time-out period on baseline sessions. For a drug test to 
be given, the monkeys were required to respond at a 
rate of 1.0 response per second or higher on all five 
cycles of the session immediately preceding the test 
session. 
During the test session, increasing doses of /-depre- 
nyl were given subcutaneously on subsequent cycles. 
Administration was cumulative in that each injection 
contained sufficient drug so that this plus the amount 
administered in previous injections was a half log-unit 
increment in total dose. In this fashion the drug was 
administered until 3.2 mg/kg /-deprenyl had been ad- 
ministered. Because this was completed in four cy- 
cles, the monkeys were exposed to a fifth 15-minute 
cycle that was preceded by an injection of saline solu- 
tion. 
RESULTS AND DISCUSSION 
Cocaine was an effective reinforcer of self-adminis- 
tration behavior in the present experiments (Fig. 1) as 
it has been in previous studies with similar schedules 
and access conditions.3° As the injection dose of co- 
caine was increased, a dose-dependent increase oc- 
curred in rates of responding, with maximum overall 
rates of lever pressing exceeding 2 responses per sec- 
ond at an injection dose of 0.01 mg/kg. In marked 
contrast, neither /-deprenyl nor its enantiomer d- 
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Fig. 1. Rates of responding maintained by different doses of 
/-cocaine (closed circles), d-deprenyl (open triangles), or 
/-deprenyl (open circles) when delivered intravenously to 
rhesus monkeys. Abscissa is drug dose in mg/kg per injec- 
tion. Ordinate is rate of responding generated when re- 
sponses produced intravenous administration of indicated 
doses; vertical lines are standard errors of mean. Where no 
SEMs are apparent, they are either within size of symbol or 
fewer than three monkeys were studied at that particular 
dose. 
deprenyl maintained the self-administration behavior 
of rhesus monkeys above saline levels (Fig. 1). An in- 
jection dose of /-deprenyl as high as 1.0 mg/kg was 
studied, which would have allowed monkeys to self- 
administer as much as 20.0 mg/kg /-deprenyl intrave- 
nously within a 25-minute session. Because a cumula- 
five subcutaneous dose of /-deprenyl of 3.2 mg/kg 
markedly depressed food-maintained responding (Ta- 
ble I), the dose range of /-deprenyl selected for eval- 
uation was clearly large enough. d-Deprenyl at doses 
up to 0.03 mg/kg per injection was also ineffective in 
maintaining self-administration. Became of a ten- 
dency for monkeys to show reduced rates of cocaine- 
maintained responding for several sessions after eval- 
uation of the reinforcing effects of 0.001 to 0.03 
mg/kg per injection of d-deprenyl, a higher dose range 
was not evaluated. In other studies that compared be- 
havioral effects of / - and d-deprenyl in rats32 or mon- 
keys,27 d-deprenyl was more potent than /-deprenyl, 
although it is less potent as an MAO-B inhibitor. Per- 
haps this is attributable to the fact that the metabolism 
of d-deprenyl results in the metabolites d-methamphet- 
amine and d-amphetamine, which are more potent 
than the metabolites of /-deprenyl, /-methamphet- 
amine and /-amphetamine, in behavioral mea- 
sures.33-35 
The major metabolite of /-deprenyl in humans is 
/-methamphetamine, which accounts for approxi- 
mately 50% of the initial metabolism of the parent 
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Fig. 2. Effects of 1.0 mg/kg /-deprenyl (open triangles) on 
rates of responding maintained by intravenous delivery of 
1-methamphetamine. Rate-maintaining effects of /-metham- 
phetamine in absence of /-deprenyl are indicated by closed 
circles. Abscissa is dose of 1-methamphetamine in mg/kg 
per injection; ordinate is response rate generated by intrave- 
nous administration of indicated doses; vertical lines are 
standard errors of mean. Where no SEMs are apparent, they 
are within size of symbol. 
Table I. Effects of cumulative doses of /-deprenyl on 
food-maintained responding 
compound.36 For example, after an oral dose of 10.0 
mg /-deprenyl to human subjects, 4.0 mg /-metham- 
phetamine and somewhat less than 1.0 mg of /-am- 
phetamine can be recovered from urine.36'37 The me- 
tabolism of deprenyl is stereospecific, with only 1- or 
d-isomers of methamphetamine, amphetamine, and 
desmethyldeprenyl resulting from metabolism of /-de- 
prenyl or d-deprenyl, respectively; there is no racemic 
transformation 36 
In the present experiments, /-methamphetamine in 
doses of 0.01 and 0.03 mg/kg per injection was an ef- 
fective reinforcer of intravenous self-administration 
behavior by the rhesus monkeys (Fig. 2). Response 
rates of more than 2 per second were maintained by 
0.03 mg/kg per injection of /-methamphetamine. 
These rates of responding were similar to the maximal 
rates of responding maintained by intravenous injec- 
tions of cocaine (Fig. 1). Because /-deprenyl is pri- 
Monkey 
E108 PA 407 
Control rate (responses/sec) 2.54 2.74 3.52 
+ 0.1 mg/kg /-deprenyl 1.96 2.52 3.82 
+0.32 mg/kg /-deprenyl 1.96 3.06 3.75 
+ 1.0 mg/kg /-deprenyl 2.28 2.61 3.69 
+ 3.2 mg/kg /-deprenyl 1.32 1.46 2.89 
30 after 3.2 /-deprenyl 
0.0001 0.001 0.01- 0.1 1.0 MG/KG/INJ I-METHAMPHETAMINE 
MG/KG/INJECTION 
0.001 0.01 0.1 
3.0 
2.5- 
2.0- 
1.5- 
1.0- 
0.5- 
0.0 
0.601 0.01 
manly metabolized to /-methamphetamine, at the 30- 
to 100-fold higher injection dose levels of /-deprenyl 
studied, any self-administered injections of /-deprenyl 
should have eventually led to blood levels of /-meth- 
amphetamine similar to those generated by /-metham- 
phetamine self-administration. However, /-deprenyl 
injection doses as high as 1.0 mg/kg did not maintain 
rates of responding above saline levels, suggesting 
that the increase in /-methamphetamine blood levels 
that resulted from the metabolism of self-administered 
/-deprenyl was not rapid enough to allow /-deprenyl to 
serve as an effective reinforcer of self-administration 
behavior under the present schedule and access condi- 
tions. It is also possible that residual /-deprenyl could 
counteract any reinforcing effects of the /-metham- 
phetamine and /-amphetamine metabolites. However, 
this is unlikely because pretreatment with 1.0 mg/kg 
/-deprenyl before self-administration sessions failed to 
alter behavior maintained by /-methamphetamine dur- 
ing the session (Fig. 2). This dose of /-deprenyl is suf- 
ficient to modify self-administration of 13-PEA.I A 
dose of 0.3 mg/kg /-methamphetamine, given to a sin- 
gle monkey, failed to modify behavior maintained by 
/-methamphetamine (data not shown). 
The lack of effect of /-deprenyl on /-methamphet- 
amine self-administration is surprising, because pre- 
session intravenous treatment with /-deprenyl should 
have resulted in appreciable blood levels of /-metham- 
phetamine during self-administration sessions. This 
failure to see altered /-methamphetamine self-adminis- 
tration behavior after presession treatment with 1.0 
3.0 
2.5- 
2.0- 
1.5- 
1.0- 
0.5- 
0.001 
MG/KG/INJ COCAINE 
Fig. 3. Effects of 1.0 mg/kg /-deprenyl (A, open triangles) or 3.2 mg/kg /-deprenyl (B, open 
circles) on behavior maintained by intravenous administration of /-cocaine. Rates of cocaine- 
maintained responding are indicated by closed circles in both graphs. Abscissae are doses of co- 
caine in mg/kg/injection; ordinates are rates of responding maintained by these doses of cocaine in 
presence and absence of /-deprenyl given intravenously 30 minutes before beginning of session; 
vertical lines are standard errors of mean. Where no SEMs are apparent, they are within size of 
symbol. 
mg/kg /-deprenyl suggests that the simple presence of 
drug at the critical receptor is not responsible for the 
reinforcing effects. Rather, a drug must have a rapid 
onset of action after each injection for it to maintain 
self-administration behavior under the conditions de- 
scribed here. 
Treatment with 1.0 mg/kg /-deprenyl in the present 
experiments also failed to produce any changes in the 
dose-response curve for 1-cocaine self-administration, 
although such treatment should have resulted in appre- 
ciable metabolite levels of /-methamphetamine and 
perhaps /-amphetamine during the self-administration 
session (Fig. 3, A). After a dose of 3.2 mg/kg /-depre- 
nyl, the monkeys responded at nearly the same rate in 
each of the four components of cocaine availability. 
For three of the four tested monkeys, this stabilized 
rate was higher than that maintained by the smaller 
two doses of cocaine and considerably lower than 
rates maintained by the larger two doses of cocaine. 
The data for these three monkeys are shown in Fig. 3, 
B. The fourth monkey, whose data were not included 
in the figure, showed the same general effect of con- 
sistent response rates throughout the session. How- 
ever, on both occasions on which this monkey was 
given 3.2 mg/kg /-deprenyl, the rates of cocaine-main- 
tained responding were very high and ranged from 3 
to 5 responses per second, independent of the dose of 
cocaine delivered as a consequence of responding. A 
fifth monkey showed a similar effect of 3.2 mg/kg 
/-deprenyl in an earlier pilot study of this dose. The 
high rates of cocaine-maintained responding in these 
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two monkeys after a high dose of /-deprenyl are con- 
sistent with the concept that /-deprenyl or its metabo- 
lites prevent the monkeys from discriminating the 
rapid onset of effects of self-administered injections of 
/-cocaine. Thus /-cocaine may lose the dose-dependent 
nature of its reinforcing effects in the presence of ele- 
vated levels of /-methamphetamine and 1-amphet- 
amine. 
A dose of 3.2 mg/kg /-deprenyl reduced slightly 
rates of food-maintained responding 15 minutes after 
cumulative subcutaneous administration and com- 
pletely suppressed this behavior 30 minutes after 
administration in each of the three monkeys studied 
(Table I). This delayed effect indicates that slowly 
appearing amphetamine metabolites of /-deprenyl are 
responsible for its rate-suppressing effects. It is inter- 
esting that the dose of /-deprenyl that, given subcuta- 
neously, completely suppressed food-maintained 
responding, when given intravenously did not com- 
pletely suppress similar rates of cocaine-maintained 
responding in any monkey and produced stimulation 
in a few subjects. It is not clear whether this differ- 
ence is related to the different routes of administration 
of /-deprenyl, and consequently a potentially different 
metabolic rate, or to a difference in the reinforcer 
maintaining behavior, perhaps reflecting an anorectic 
effect of the amphetamine metabolites of /-deprenyl. 
/-Deprenyl has recently been suggested as a medica- 
tion for the treatment of various types of drug abuse. 
Such a use is postulated on the basis of its ability at 
certain doses to facilitate dopaminergic functions ei- 
ther by directly blocking reuptake of dopamine3839 or 
by elevating 13-PEA levels12 and thus stimulating do- 
pamine release and/or potentiating postsynaptic ac- 
tions of dopamine. Although the present results do not 
indicate that /-deprenyl would be of use in selectively 
modifying ongoing use of cocaine or other stimulants, 
it is possible that it might have effects in preventing 
relapse to drug use after drug use is terminated by 
other treatments. Such an effect could perhaps be me- 
diated by amelioration of certain symptoms of drug 
withdrawal that might otherwise serve to trigger return 
to use of drugs. 
We thank Dr. Jack Bergman for his prior discussion and 
helpful suggestions and appreciate the technical efforts of 
Brenda Winger, Debbie Huntzinger, and Lisa McMahon in 
carrying out these studies. 
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